Researchers find 4 potential COVID treatments through AI (2021/02/23)
其它新聞 Other News   
  • CECC defends safety profile of AstraZeneca vaccine
  • King of Eswatini reveals he was treated for COVID by Taiwan doctors in January
  • Pandemic drives traffic to Taiwan’s 1922 public hotline
  • At Shulin Industrial Park, another step forward for energy transition
  • Committee may leave electricity rates unchanged for sixth time in a row: analyst
  • New Taiwan Lottery app checks your scratch card for the winning numbers
  • Drier spring in forecast, with no respite for drought-stricken areas
  • Cheng Yu-hsuan creates chocolates that are the true taste of Taiwan
  • Macaque at Hsinchu Zoo explores the joys of smartphone ownership
  • Lohas Cherry Blossom Festival blooming till Feb. 28
  • Yunlin farmer produces giant dragon fruit weighing 1.6 kilos
  • 英文 English 
    Researchers find 4 potential COVID treatments through AI (2021/02/23)

    Using the power of artificial intelligence, Taiwan researchers have found four drugs that may be able to inhibit the COVID virus. One promising drug is JMY206, an anti-inflammatory therapy that was dozens of times more effective against COVID-19 than Remdesivir. Partial results of this study were published in ACS Nano, a journal by the American Chemical Society.

    The research team at National Yang Ming Chiao Tung University used AI and SARS datasets to identify key proteases in the COVID virus and see whether different FDA-approved drugs could inhibit them. Three other drugs that showed promise against the COVID virus were hepatitis C treatments Boceprevir and Telaprevir, as well as Nelfinavir, which treats HIV.
    中文 Chinese  
    陽明交大以AI找出C肝老藥物 抑制新冠病毒

    陽明交大團隊透過AI技術,找出4款舊藥可以抑制武漢肺炎病毒活性,其中一款抗發炎藥,經動物實驗證實,效力比起瑞德西韋強數十倍,為治療武漢肺炎帶來一線曙光,部分成果已發表在《美國化學學會月刊:奈米領域(ACS Nano)》。

    關於民視 常見問題 如何收看民視 意見信箱

    © 2009 FTV All Rights Reserved 版權所有‧盜用必究 Designed by FTV
    地址:244 新北市林口區信義路99號   觀服電話:(02)8601-8601 服務時間:週一至週日09:00-21:00   傳真:(02)8601-3955

    本網站使用 cookie 與其他技術為您提供更好的使用體驗, 請閱讀我們的的隱私權政策,通過使用我們的網站,表示您確認並同意我們的政策。